Skip to main content

Articles By Jack Cush, MD

RheumNow Podcast square

Hmmm Really? (7.11.2025)

Dr. Jack Cush reviews the news and journal reports from this past week - some obvious, other new thoughts and some - hmmm, reallly?

Read Article
cancer search news magnify

No Increased Malignancy Risk with Ixekizumab

A pooled analysis of 25 randomized clinical trials affirms the safety of ixekizumab (IXE) when used to treat patients with psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA).

Read Article
Vexas

Overview of the VEXAS Syndrome

A current systematic review in Rheumatology addresses the clinical features seen in the VEXAS syndrome.

Read Article
38420215_s.jpg

Cancer Survival Outcomes in Autoimmune Skin Disease Patients

Patients with autoimmune skin diseases (ASDs) with cancer had significantly better cancer survival outcomes than those without ASD, suggesting coexistant autoimmune or inflammatory disease does not adversely affect a cancer prognosis.

Read Article
psoriatic.PIP_.JPG

Early DMARD Initiation Benefits in Psoriatic Arthritis

Mease et al has published the results of a cohort study showing early initiation of disease-modifying antirheumatic drugs (DMARDs) in patients with psoriatic arthritis (PsA) resulted in better outcomes compared to late initiation.

Read Article
guidelines.recommendations.jpg

ICYMI: Consensus Against Interventional Injections for Chronic Spinal Pain

BMJ has published a clinical practice guideline resulting from the work of an international, multidisciplinary panel addressing chronic spine pain (≥3 months duration) not associated with cancer or inflammatory arthropathy. This is a chronic (not acute) spine pain guideline.

Read Article
pills-384846_640%20%281%29.jpg

ICYMI: Should Lupus Nephritis Receive PJP Prophylaxis?

A current review article suggests that the need for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in patients with systemic lupus erythematosus (SLE) and lupus nephritis will need to be individualized based on therapies and risk factors.

Read Article
Weed, THC

ICYMI: ACP: Best Practice Advice on Cannabis or Cannabinoids Use for Chronic Noncancer Pain

The American College of Physicians published a best practice advisory on cannabis or cannabinoids in the Annals of Internal Medicine.

Read Article
cancer.cross_.jpg

ICYMI: Channeling Bias and Cancer Risk with Biologic or Targeted Synthetic DMARDs

A retrospective US administrative claims cohort study of RA patients on tumor necrosis factor inhibitors (TNFis), non-TNFi biologics, or Janus kinase inhibitors (JAKis) found a statistically significantly higher risk of incident cancer in patients receiving rituximab, abatacept, or JAKis (compared with TNFis).

Read Article
Hepatitis B (Keep)

ICYMI: AGA Guideline: Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals

The American Gastroenterology Association has published its revised clinical practice guidelines for the prevention and treatment of hepatitis B virus (HBV) reactivation in at-risk patients, particularly those with immune-mediated disease, receiving immunomodulatory therapy and steroids.

Read Article
×